The disclosure relates to the use of an opioid agonist or a pharmaceutically acceptable salt thereof and an opioid antagonist or a pharmaceutically acceptable salt thereof in the manufacture of an oral pharmaceutical dosage form to treat Parkinson&rsquos disease and/or at least one symptom thereof, wherein the opioid agonist is selected from the group consisting of morphine, oxycodone, hydromorphone, dihydroetorphine, etorphine, nalbuphine, propoxyphene, nicomorphine, dihydrocodeine, diamorphine, papaveretum, codeine, ethylmorphine, phenylpiperidine, methadone, dextropropoxyphene, buprenorphine, pentazocin, tilidine, tramadol, tapentadol, hydrocodone and pharmaceutically acceptable salts thereof and the opioid antagonist is naloxone or a pharmaceutically acceptable salt thereof.
